EANM’05 – CME Session VIII
October 17, 2005, 16:30 – 18:00
EANM-SNM Joint Seminar: Dementia Imaging: Metabolism, Blood Flow and Beyond
Moderator: K. Tatsch (Munich)
Co-Moderator: F. Nobili (Genoa)
Upon completion of this course the attendee will be able to:
- Review the clinical phenomenology and histopathology of Alzheimer’s and related neurodegenerative diseases
- Discuss the range of radiopharmaceuticals for brain imaging in dementia with description of the relative advantages and disadvantages of these radioligands as biomarkers in Alzheimer’s patients.
- Describe the range of current clinical roles for neuroimaging markers in Alzheimer’s, mild cognitive impairment (MCI), and related dementias and the current evidence-based support for these neuroimaging applications.
- Examine the current research issues in the use of neuroimaging markers to monitor disease status, progression, and new novel treatment-approaches.
This session is designed to provide the participant with a state-of-the art assessment of the emerging role of neuroimaging in the clinical management and research of Alzheimer’s dementia (AD), Mild Cognitive Impairment (MCI) and related disorders. There will be strong emphasis on the roles of neuroimaging from the perspective of current clinical applications in AD and other neurodegenerative disorders including early and accurate diagnosis, clinical monitoring of disease, and issues and opportunities with the use of new radiopharmaceuticals and neuroimaging techniques in clinical trials of next-generation therapeutic agents.
- Neurodegenerative dementia
- mild cognitive impairment
- Alzheimer’s dementia
- glucose metabolism